Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

leuprolide acetate for injectable suspension TOL2506

A subcutaneous injectable suspension formulation containing the acetate salt form of leuprolide, a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon subcutaneous administration of the leuprolide acetate for injectable suspension TOL2506, leuprolide binds to and activates the gonadotropin-releasing hormone receptor (GnRHR). The continuous stimulation of GnRHR by leuprolide results in both the desensitization of pituitary GnRHR and the inhibition of pituitary secretion of the gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH). In males, this results in a significant decline in testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression. In females, this decreases estradiol production and level, suppresses ovarian function and may inhibit proliferation of estrogen receptor (ER)-positive breast cancer.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:TOL 2506
TOL-2506
TOL2506
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search